COMBINATION THERAPY OF BENIGN PROSTATIC HYPERPLASIA USING DRUGS PROSTERID AND SONIZIN

The results of the study aimed to evaluation of efficacy and safety of combined use of drugs finasteride (Prosterid 5 mg) and tamsulosin (Sonizin 0.4 mg) for the treatment of patients with benign prostatic hyperplasia (BPH) are presented. The study included 75 patients with BPH aged 50 years, with moderate and severe symptoms of disease, moderate intravesical obstruction, prostate volume ≥ 30 cm3, and the level of prostate-specific antigen ≤ 10 ng/ml. The length of treatment was 275 ± 9 days in all groups. Patients were randomized into three groups, comparable in age, clinical manifestations and laboratory and instrumental parameters: 35 patients of Group 1 received a combined therapy with Prosterid 5 mg/day and Sonizin 0.4 mg/day, 20 patients of Group 2 - monotherapy with Prosterid 5mg/day, and 20 patients of Group 3 - monotherapy with Sonizin 0,4 mg/day. The clinical study showed that prolonged combination therapy with Prosterid and Sonizin leads to reduction of the prostate gland volume in addition to reduction of severity of intravesical obstruction caused by BPH. It makes it possible to use this treatment to reduce the risk of acute urinary retention and reduce the need for surgical intervention.

benign prostatic hyperplasia, combination therapy, Prosterid, Sonizin